.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Chubb
Merck
Mallinckrodt
US Army
Express Scripts
US Department of Justice
Boehringer Ingelheim
Citi
Johnson and Johnson

Generated: December 16, 2017

DrugPatentWatch Database Preview

Sanofi-aventis Us Company Profile

« Back to Dashboard

What is the competitive landscape for SANOFI-AVENTIS US, and when can generic versions of SANOFI-AVENTIS US drugs launch?

SANOFI-AVENTIS US has six approved drugs.

There are twenty-nine US patents protecting SANOFI-AVENTIS US drugs.

There are four hundred and twenty-four patent family members on SANOFI-AVENTIS US drugs in forty-four countries and fifty-three supplementary protection certificates in thirteen countries.

Summary for Sanofi-aventis Us

International Patents:424
US Patents:29
Tradenames:4
Ingredients:3
NDAs:6
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi-aventis UsADLYXINlixisenatideSOLUTION;SUBCUTANEOUS208471-001Jul 27, 2016RXYesYes► Subscribe► SubscribeY► Subscribe
Sanofi-aventis UsADLYXINlixisenatideSOLUTION;SUBCUTANEOUS208471-001Jul 27, 2016RXYesYes► Subscribe► SubscribeY► Subscribe
Sanofi-aventis UsADLYXINlixisenatideSOLUTION;SUBCUTANEOUS208471-001Jul 27, 2016RXYesYes► Subscribe► SubscribeY► Subscribe
Sanofi-aventis UsADLYXINlixisenatideSOLUTION;SUBCUTANEOUS208471-001Jul 27, 2016RXYesYes► Subscribe► SubscribeYY► Subscribe
Sanofi-aventis UsSOLIQUA 100/33insulin glargine; lixisenatideSOLUTION;SUBCUTANEOUS208673-001Nov 21, 2016RXYesYes► Subscribe► SubscribeY► Subscribe
Sanofi-aventis UsADLYXINlixisenatideSOLUTION;SUBCUTANEOUS208471-001Jul 27, 2016RXYesYes► Subscribe► SubscribeY► Subscribe
Sanofi-aventis UsADLYXINlixisenatideSOLUTION;SUBCUTANEOUS208471-001Jul 27, 2016RXYesYes► Subscribe► SubscribeY► Subscribe
Sanofi-aventis UsSOLIQUA 100/33insulin glargine; lixisenatideSOLUTION;SUBCUTANEOUS208673-001Nov 21, 2016RXYesYes► Subscribe► SubscribeY► Subscribe
Sanofi-aventis UsXYZAL ALLERGY 24HRlevocetirizine dihydrochlorideSOLUTION;ORAL209090-001Jan 31, 2017OTCYesNo► Subscribe► SubscribeY► Subscribe
Sanofi-aventis UsSOLIQUA 100/33insulin glargine; lixisenatideSOLUTION;SUBCUTANEOUS208673-001Nov 21, 2016RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Sanofi-aventis Us

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi-aventis UsXYZALlevocetirizine dihydrochlorideSOLUTION;ORAL022157-001Jan 28, 2008► Subscribe► Subscribe
Sanofi-aventis UsXYZALlevocetirizine dihydrochlorideTABLET;ORAL022064-001May 25, 2007► Subscribe► Subscribe
Sanofi-aventis UsXYZALlevocetirizine dihydrochlorideTABLET;ORAL022064-001May 25, 2007► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for SANOFI-AVENTIS US drugs

Drugname Dosage Strength Tradename Submissiondate
levocetirizine dihydrochlorideOral Solution0.5 mg/mLXYZAL1/14/2009
levocetirizine dihydrochlorideTablets5 mgXYZAL12/17/2007

Non-Orange Book Patents for Sanofi-aventis Us

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,574,198Drive mechanisms suitable for use in drug delivery devices► Subscribe
9,205,197Drug delivery device dose setting mechanism► Subscribe
7,553,299Drive mechanisms suitable for use in drug delivery devices► Subscribe
8,663,175Drive mechanisms suitable for use in drug delivery devices► Subscribe
9,526,843Drive mechanisms suitable for use in drug delivery devices► Subscribe
8,876,782Drive mechanisms suitable for use in drug delivery devices► Subscribe
8,070,727Drive mechanisms suitable for use in drug delivery devices► Subscribe
7,935,088Drive mechanisms suitable for use in drug delivery devices► Subscribe
8,888,750Pen-type injector► Subscribe
6,528,486 Peptide agonists of GLP-1 activity► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Sanofi-aventis Us Drugs

Country Document Number Estimated Expiration
Canada2669363► Subscribe
World Intellectual Property Organization (WIPO)2004078239► Subscribe
Spain2332462► Subscribe
South Korea20170100037► Subscribe
Russian Federation2494765► Subscribe
Israel214157► Subscribe
Argentina063838► Subscribe
Japan5271411► Subscribe
Portugal2263723► Subscribe
Austria497398► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Sanofi-aventis Us Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0885961/01Switzerland► SubscribePRODUCT NAME: INSULIN GLULISIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57013 02.05.2005
C0009France► SubscribePRODUCT NAME: INSULINE GLULISINE; REGISTRATION NO/DATE IN FRANCE: EU/1/04/258/001 DU 20040927; REGISTRATION NO/DATE AT EEC: EU/1/04/285/001 DU 20040927
2/2005Austria► SubscribePRODUCT NAME: INSULIN GLULISINE
2017 00013Denmark► SubscribePRODUCT NAME: KOMBINATION AF INSULIN DEGLUDEC OG LIRAGLUTID; NAT. REG. NO/DATE: EU/1/14/947 20140922; FIRST REG. NO/DATE: CH 65041 20140912
C/GB05/024United Kingdom► SubscribePRODUCT NAME: INSULIN GLULISINE OR A PHYSIOLOGICALLY TOLERABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/04/285/001 - 020 20040929
C0021France► SubscribePRODUCT NAME: LIXISENATIDE; REGISTRATION NO/DATE: EU/1/12/811/001 20130201
2004005Lithuania► SubscribePRODUCT NAME: INSULIN DETEMIR
2017000040Germany► SubscribePRODUCT NAME: SCHNELL-WIRKENDES INSULIN ASPART; REGISTRATION NO/DATE: EU/1/16/1160 20170109
90036-0Sweden► SubscribePRODUCT NAME: KOMBINATION AV INSULIN DEGLUDEK OCH INSULIN ASPART; REG. NO/DATE: EU/1/12/806/001 20130121
60026Netherlands► SubscribePRODUCT NAME: INSULINUM LISPRUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/96/007/001 - EU/1/96/007/003 19960430
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
Deloitte
Cantor Fitzgerald
Novartis
Mallinckrodt
Harvard Business School
Moodys
Accenture
Cerilliant
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot